we have a track record of nurturing and investing in emerging life science and tech companies
The biotech sector is one of the leading sectors in the UK economy. The large pharma companies now rely on the small innovative biotech’s for new ideas in disease areas such as cancer and neurosciences amongst others which has led to higher potential exit valuations. The fund will help widen the community of investors that will help expand early stage research in the UK.

The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years.

Sunil Shah co-founded o2h Ventures Ltd with his brother Prashant Shah in the year 2018. o2h operate from their proprietary 2.7 acre The Mill SciTech Park where they are developing a unique model for incubating small life science companies.

Cambridge hotbed for emerging talents
o2h has acquired the 2.76 acre heritage Hauxton Mill site, Cambridge, UK with plans to develop it into the o2h SciTech Park to create one of the region’s most exciting community of entrepreneurs in life-science, technology and social enterprise.

history in grassroots science
The team and the advisors operating o2h ventures have been active in grassroots science for over 20 years in the UK. They have developed a strong pipeline of early stage opportunities and have developed a model for assisting these small companies through key decisions and their unique resource requirements.
access to scientific talents
The team at o2h has developed access to some of the most interesting scientific ideas and talents in the UK, achieving a clearly differentiated position through its live working relationships, fostered over many years, working as a discovery services company. This potentially gives o2h earlier access than competitors to some of the most promising companies.

business model
The business model identified by o2h gives it an edge both in terms of access to opportunities as well as an understanding of the support they require post-investment in terms of incubation. o2h formulated its two-part differentiation by observing the approach of China’s Wuxi Ventures to access, and the approach of the USA’s Atlas Ventures with regards to incubation. The team believes combining these two approaches will increase the Fund’s prospects of making successful exits.
evaluation
Over the years, the o2h group has developed a rigorous process to evaluate its deal-flow for the purpose of making seed investments. The team will start out by screening companies that meet simple criteria of having a clear, novel, transformative drug therapeutic focus. The investment evaluation committee will assess each project for its scientific tractability where appropriate in conjunction with accomplished scientific advisors. The evaluation process will include an analysis of the rationale of the preclinical target, IP position, path to, and through the clinic as well as the determination of the team to navigate and overcome challenging hurdles. o2h will also attempt to speak with potential acquirers of the company (mainly big pharma) during the evaluation process to determine if the company could be an interesting acquisition target should the company meet its scientific end goal.

Speak to a member of our team